Abundnz B.V. is a Dutch SME that offers advanced analytical support for biotechnology and diagnostics industries and life science research worldwide. With the use of mass spectrometry, we characterize innovative medicines like peptide and protein drugs, oligonucleotides and targeted drug delivery systems and we discover and validate biomarkers. Abundnz has a unique technology to determine the clearance profile of innovative medicines in an early phase of drug development.

Ultra sensitive assay for pre-clinical studies with proteins, peptides and nanomedicines

What we offer

Our company has developed a technology platform of ultra sensitive assays for pre-clinical studies with proteins, peptides and nanomedicines. The technology is based on proprietary methods for labelling and sample preparation, with subsequent mass spectrometry measurements. The method is 1.000 more sensitive than currently applied techniques like ELISA and LC-MS. The technology enables microdose/phase 0 studies with biologicals and is also helpful in case of immunogenicity of protein drugs or when such drugs are just in minute amounts available.
The offered technology is a very straightforward and novel concept, making it an attractive and cost-effective way to study the behaviour of biologicals in an early stage of drug development.

What we are looking for

We are looking for collaboration with partners from industry and consortia with academia for testing biologicals (proteins, antibodies, peptides, oligonucleotides, nanomedicine) with our technology in pre-clinical (animal) studies or phase 0 (human) studies.

Collaboration sought

  • Research & Development
  • Commercial Agreement


Mr Dr. Ir. Robert-Jan Lamers

Managing director and founder
back to list